Targeted drugs against breast cancer are being developed centering around ones targeting HER2. In addition to trastuzumab and lapatinib that were already approved in Japan, promising drugs are being developed one after another. Basic mechanisms of their action and resistance emergence are being clarified step by step. In consideration of extraordinarily high medical expenditures of targeted drugs compared with conventional cytotoxic anticancer agents, it is critical to choose a targeted drug from a standpoint that it has definitely different features besides high efficacy and it has predictive factors which enable accurate anticipation of effects or adverse events. It will be confusing for the time being how each targeted drug is used properly in terms of the prescription order or combinations with chemotherapy. Over the middle-or long-term, clinical trials comparing these drugs will be conducted until clinically effective and easy-to-use targeted drugs in a true sense survive. Clinical handling of targeted drugs is not easy if conducted in the conventional way. Whereas conventional cytotoxic anticancer agents have major adverse events like nausea/vomiting or myelosuppression in common, such a variety of side effects occur in the use of targeted drugs as vary greatly according to different mechanisms of action of individual drugs. Oncologists will be required to master appropriate initial therapy to treat them; on the other hand, oncologists need to cooperate with specialists in other fields more than they used to.
INTRODUCTION
The story of targeted therapy for breast cancer is old. Endocrine therapy has been successful targeted therapy for decades in breast cancer. Tamoxifen, in particular, has now been widely used for its excellent efficacy as well as its scarceness of toxic effects (1 -3) . However, targeted therapy has changed dramatically over the last decade. The development of targeted drugs has become based on the identification of the precise molecular abnormalities that are responsible for malignant progression in human cancers. The identification of signaling pathways responsible for inhibition of apoptosis, progression, cellular invasion and metastasis have generated several targets for new anticancer drugs.
At present, targeted drugs against breast cancer are being developed centering around ones targeting HER2. In addition to trastuzumab and lapatinib that were already approved in our country, promising drugs such as pertuzumab, trastuzumab-DM1 and neratinib are being developed one after another. Basic mechanisms of their action and resistance emergence are being clarified step by step.
I would like to review the current status and future directions of targeted therapy in breast cancer.
The receptors are located at the cell membrane consisting of extracellular ligand binding domains and a transmembrane domain. Several ligands have been found that bind HER1, HER3 and HER4 including transforming growth factor a, EGF and heregulins. No known natural ligand exists for HER2. HER2 positive tumors account for 25 -30% of all breast cancers. These tumors tend to be more aggressive than HER2 negative tumors and are associated with poorer prognosis (4) .
All receptors except HER3 have an intracellular tyrosine kinase domain. Signal transduction cascades lead to cellular changes in growth, differentiation, angiogenesis, adhesion and apoptosis.
Multiple angiogenic factors are commonly expressed by breast cancers; the 121-amino-acid isoform of vascular endothelial growth factor (VEGF) predominates (5) . VEGF regulates endothelial cell proliferation, migration and gene expression, inhibits endothelial apoptosis, increases vascular permeability and vasodilatation (6) . Differences in function among the various VEGF isoforms are not well defined, although VEGF-C has a key role in lymphangiogenesis, whereas VEGF-A is more potent in inducing vasodilatation and pathologic angiogenesis (7).
TARGETED THERAPY FOR BREAST CANCER
At present, several new targeted therapies are in clinical trials testing their efficacy for breast cancer.
The therapeutic strategy for breast cancer with the use of targeted drugs is, at present, mainly focused on coping with HER2. We have already lapatinib, a HER1 and 2 dual inhibitor that was approved in April 2009 and trastuzumab that is in widespread use. I expect these two drugs to be tried distinctively in clinical settings for the time being.
Other promising anti-HER2 agents include a series of such agents as pertuzumab, trastuzumab-DM1 and neratinib. There are a lot of hopeful drug candidates like bevacizumab which is an anti-VEGF-A antibody, everolimus which is an inhibitor of mTOR, and sunitinib and sorafenib called multitarget drug. Many of them have been approved for other cancers and information on their safety is being collected little by little. International multicentre clinical trials joined also by Japan are ongoing for each drug. We are now interested that these drugs can be used in clinical practice as soon as possible. It will be confusing for the time being how each drug is used properly in terms of the prescription order or combinations with chemotherapy. Over the middle-or long-term, clinical trials comparing these targeted drugs will be conducted until clinically effective and easy-to-use drugs in a true sense survive.
SIDE EFFECTS OF TARGETED THERAPIES
It is coming to light that clinical handling of targeted drugs is not easy if conducted in the conventional way. Whereas conventional cytotoxic anticancer agents have major adverse events like nausea/vomiting or myelosuppression in common even though they differ in severity, such a variety of side effects occur in the use of targeted drugs as vary greatly according to different mechanisms of action of individual drugs. For example, bevacizumab may cause hypertension, proteinuria or hemorrhage, although sunitinib may bring about hyperglycemia or hypothyroidism. These side effects have not ever been experienced by any oncologists and can be lethal. Therefore, on the one hand, oncologists will be required to master appropriate initial therapy to treat them; on the other hand, oncologists need to cooperate with specialists in other fields more than they used to.
CLINICAL EVIDENCE ON TREATMENT WITH TARGETED THERAPY BEYOND PROGRESSION
Change of treatment at disease progression is a general principle in oncology. Clinical evidence on treatment with trastuzumab beyond progression either alone or with a switch to a different chemotherapy is based, so far, on various retrospective analyses (8, 9) . However, these results might be biased as a result of unknown factors that influence physicians' decisions to stop or to continue trastuzumab. Phase III trial demonstrated continuation of trastuzumab plus capecitabine showed a significant improvement in response rate and time to progression compared with capecitabine alone in women who experienced progression during trastuzumab treatment (10) . Preliminary data showed the combination of trastuzumab and pertuzumab appeared to be more active than either drug alone. The combination was also active in patients that had failed both antibodies given separately (11) . As mentioned above, a drug, that is determined as ineffective according to the current criteria, can be effective if used in combination with an alternative drug. This phenomenon is encountered not infrequently, which may elude common knowledge or experiences of oncologists. Oncologists should keep this point in mind.
REPRESENTATIVE DRUGS TRASTUZUMAB
Trastuzumab, the first HER2-targeted agent approved for clinical use in breast cancer patients, is a humanized monoclonal antibody that binds to the extracellular domain of the HER2 receptor. In 2001, a pivotal study by Slamon et al. (12) showed the clinical benefits of trastuzumab in metastatic HER2 positive breast cancer. Large multicenter randomized trials revealed that trastuzumab as adjuvant treatment for 1 year was effective in HER2 positive breast cancer (13, 14) . Trastuzumab has been without a doubt a major success story in the field of targeted drugs. Despite its initial efficacy, acquired resistance to trastuzumab develops in a majority of patients with metastatic breast cancer, and a large subset never responds. The time has come to improve upon the success of trastuzumab by recognizing its limitations.
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LAPATINIB
Lapatinib is an oral dual tyrosine kinase inhibitor targeting HER1 and HER2, with a consequence of blocking the downstream signaling pathways from these receptors. Phase III trial showed lapatinib plus capecitabine was superior to capecitabine alone with regard to time to progression in HER2 positive advanced breast cancer that had progressed after treatment with regimens that included anthracycline, taxane and trastuzumab (15) . The role of lapatinib for firstline therapy is undefined. Phase III clinical trial of taxane based chemotherapy with lapatinib or trastuzumab as first-line therapy for HER2 positive metastatic breast cancer is now on going. Until more data are available, use of lapatinib should be restricted to trastuzumab-refractory and chemorefractory HER2 positive metastatic breast cancer. In a small group of patients with brain metastasis, previously exposed to trastuzumab, lapatinib showed a real activity (16) . Because of the good results of lapatinib treatment on metastatic breast cancer and a low incidence of cardiotoxicity, lapatinib is a potentially ideal therapy for the adjuvant treatment in early stage breast cancer patients. Two such adjuvant trials, TEACH (Tykerb Evaluation After Chemotherapy) and ALTTO (Adjuvant Lapatinib and/or Trastuzumab Trial Organization), are used in the work.
PERUTUZUMAB
Pertuzumab, a monoclonal antibody directed against HER2 at domain II, sterically blocks dimerization of HER2 with HER1 and 3. Thus, the drug would be expected to inhibit signaling from HER2/HER1 and HER2/HER3 heterodimers. Pertuzumab and trastuzumab bind to different epitopes in the extracellular domain of HER2 (17) . Early clinical study has shown that the drug is well tolerated and clinically active (18) . The main adverse events were diarrhea, fatigue, nausea, vomiting and rash, but most were mild to moderate. The combination of trastuzumab plus pertuzumab combined with chemotherapy is being evaluated in first-line metastatic breast cancer patients in CLEOPATRA (CLinical Evaluation Of Pertuzumab and TRAstuzumab).
NERATINIB
Neratinib is a potent, orally administered, small-molecule, irreversible pan HER inhibitor that inhibits HER1, 2, 4. The compound has been well characterized for its biological activities in several preclinical models. It inhibits the growth of tumor cells in cell lines and xenografts that express HER1 and 2 (19) . Phase I study revealed the most common toxicity was diarrhea (20) . Antitumor activity was observed in patients with breast cancer who had previous treatment with trastuzumab, anthracyclines and taxanes (20) . Randomized phase III trials are now on going in metastatic and adjuvant settings.
SUNITINIB
Sunitinib is an oral tyrosine kinase inhibitor that has multiple targets, including VEGF receptor, platelet-derived growth factor receptor, c-kit and Flt-3 (21) . Phase II study showed sunitinib was active in patients with heavily pretreated metastatic breast cancer. Most common adverse events were fatigue, nausea, diarrhea, mucosal inflammation and anorexia which were of mild-to-moderate severity and manageable with supportive treatment and/or dose modification (22) .
BEVACIZUMAB
Bevacizumab is a humanized monoclonal antibody directed against all isoforms of VEGF-A. The binding of VEGF initiates downstream signaling, which in turn enhances endothelial cell survival, proliferation, permeability, migration and invasion. In a phase III trial, the addition of bevacizumab to capecitabine in patients previously treated with anthracyclines and taxanes significantly increased the objective response rate but not progression-free survival or overall survival (23) . E2100 trial compared paclitaxel alone with paclitaxel plus bevacizumab as initial therapy for patients with metastatic breast cancer and the combination therapy prolonged progression-free survival, but not overall survival, when compared with paclitaxel alone (24) .
PROBLEMS TO BE CONQUERED

MOLECULAR BASIS OF TREATMENT FAILURE: POSSIBLE MECHANISMS OF RESISTANCE
Elucidation of possible mechanisms of resistance for either targeted drug is crucial. Defined main mechanisms of resistance for trastuzumab are listed in the following.
PTEN LOSS AND PI3K MUTATION
PTEN is a molecule that works to suppress the signal transduction pathway in the cell, whereas PI3K stimulates the pathway. Approximately 50% of patients with breast cancer have a mutation or loss of at least one copy of the PTEN gene and decreased PTEN expression has been shown to be associated with poorer prognosis (25) . It has recently been found that patients who have PTEN positive tumors derive the maximum benefit from trastuzumab compared with those with PTEN negative tumors (26) . Lapatinib does not seem to have this mutual relationship with PTEN. Mutation of PI3K was reported to be important for mechanisms of resistance for trastuzumab (27) .
ABNORMALITY OF THE EXTRACELLULAR DOMAINS OF HER2 RECEPTOR
HER2 has 4 functional extracellular domains, structural changes of which lead to trastuzumab failing to bind to the domain, resulting in trastuzumab resistance. It is p95HER2, of which the extracellular domain is cleaved, that has been most extensively investigated. The extracellular domain of HER2 might be cleaved by proteases, creating a truncated receptor to which trastuzumab is unable to bind. They arise through either proteolytic shedding of the extra cellular domain of full-length HER2 (28) or by primary defect in HER2 receptor formation (29) . Patients with metastatic breast cancer who were treated with trastuzumab, 11.1% expressing p95HER2 responded to trastuzumab, whereas 51.4% with tumors expressing full-length HER2 achieved good response (30) . No clinical data are available on the relationship between expression of p95HER2 and efficacy of lapatinib.
The membrane-associated glycoprotein mucin-4 (MUC4) might mask HER2, preventing it from binding effectively to trastuzumab. In vitro, the MUC4 protein level is correlated to resistance and inversely correlated with trastuzumab binding capacity (31) .
INCREASED SIGNALING FROM OTHER RECEPTORS ACTIVATING THE MAPK AND PI3K
Insulin-like growth factor 1 receptor (IGF1R) is responsible for a wide spectrum of cellular functions (32) . Overexpression of IGF1R is also associated with trastuzumab resistance, as this receptor physically interacts with and phosphorylates HER2 (33) . Trastuzumab sensitivity was lost in breast cancer cells overexpressing both HER2 and IGF1R. Signaling via activated IGF1R induces downregulation of p27 kip which is responsible for trastuzumab-induced apoptosis (34) . Furthermore, in trastuzumab-resistant cells, IGF1R can physically heterodimerize with HER2 and induce more rapid proliferative signals (35) . Co-expression of IGF1R and HER2 predicted a favorable outcome to lapatinib monotherapy was reported (36) .
DRUG EXPENDITURES
Generally, targeted drugs are expensive, reflecting enormous research expenses for their development. Drug expenditures are to be expanded as target patients increase according to changing indications varying from metastatic or recurrent tumors to early cancer that should be prevented from recurrence. Japan has a nationwide comprehensive health insurance system, which pays back a portion of medical costs exceeding a certain amount by insurance to cover major medical expenses, so that individual patients are exempted from payment of an excess over a certain amount of medical costs they owe. Naturally, however, total national costs are enormous.
Medical costs are feared to expand with spread of multidrug therapy using targeted drugs. In future, the conception of cost effectiveness plays a key role more often in decisions on approval of drugs on the government side or on therapeutic drug choice on the physician side. In fact, National Institute of Clinical Excellence in England makes decisions based on the cost effectiveness principle, being exemplified by the fact that trastuzumab has been approved for breast cancer but bevacizumab not for colon cancer.
MORE DEFINITELY SELECTED PATIENTS: SEARCH OF BIOMARKERS
In consideration of extraordinarily high medical expenditures of targeted drugs compared with conventional cytotoxic anticancer agents, it is critical to choose a targeted drug from a standpoint that it has definitely different features besides high efficacy and it has predictive factors which enable accurate anticipation of effects or adverse events.
Although the discovery of trastuzumab and lapatinib represents a real breakthrough in treating HER2 positive breast cancer, each still has a response rate around 30% as single agent in first-line treatment of HER2 positive breast cancer (37) . This means that around 70% of patients will not derive any benefit from treatment with either agent. Furthermore, the majority of responders will start to progress within 1 year of treatment initiation, elucidating the potential mechanisms by which HER2 positive breast cancer cells would escape the cytotoxic effects of these agents. Namely, conventional methods cannot afford to predict efficacy of trastuzumab. At present, biomarkers are being aggressively searched for concerning individual targeted drugs under development. Biomarkers such as those related to cell proliferation, cell cycles, angiogenesis or signal transduction are included in candidate molecules. Because the discovery of efficient biomarkers cannot be accomplished without linkages with clinical information, comprehensive search is mandatory paying thoughtful attention to personal data protection as well as ethics.
A stance 'proper drug for proper patient' will be more rigidly called on.
PROSPECT OF BREAST CANCER THERAPY
Recent gene expression studies have identified several distinct breast cancer subtypes. These include two main subtypes of estrogen receptor (ER)-negative tumors, basal-like and HER2-enriched and two subtypes of ER-positive tumors, luminal A and luminal B (38) . These subtypes differ markedly in prognosis and in the therapeutic targets they express. New drugs will be developed focusing on these molecular subtypes. I can give Poly (ADP-ribose) Polymerase-1 (PARP-1) inhibitor for basal-like breast cancer as an example.
The BRCA1 pathway is assumed to be abnormal in basallike breast cancer, which may have therapeutic implications since this pathway is important in DNA repair. BRCAdeficient cells appear to be particularly sensitive to inhibition of PARP-1, which is a DNA-binding protein involved in detection and repair of DNA strand breaks (39) .
A preliminary report of a randomized phase II trial of cytotoxic agents with or without the PARP-1 inhibitor in patients with metastatic triple-negative breast cancer, which
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Targeted therapy in breast cancer shares molecular features with BRCA1-related breast cancers, showed promising efficacy (40) . Multidrug therapy was introduced on the idea that simultaneous use of drugs with most different mechanisms of action at a tolerable level of adverse events would be expected to take a stronger action against cancer. This treatment concept is generally accepted in therapies employing cytotoxic anticancer agents. This concept is also naturally looked for in targeted drugs. For example, although trastuzumab and lapatinib target the same receptor, HER2, their combination could be attractive, since they attack different parts of the receptor: trastuzumab is against the extracellular, lapatinib against the intracellular domains, trastuzumab increases the internalization and degradation of HER2, lapatinib inhibits the tyrosine kinase activity. In phase III trial of 296 women with metastatic breast cancer refractory to multiple trastuzumabcontaining regimens who were randomly assigned to lapatinib with or without trastuzumab. Progression-free survival and overall survival were significantly longer with dual therapy even though about half of patients who allocated to lapatinib arm were allowed to receive lapatinib with trastuzumab after disease progression (41) .
Both regimens of neratinib þ trastuzumab and pertuzumab þ trastuzumab were also reported to be superior in their effects to single agents alone (11, 42) .
Although a multidrug therapy with targeted drugs is certainly attractive, we have to await data accumulation to confirm that factitious simultaneous inhibition of multiple targets is safe, life prognosis is clearly better compared with sequential use of single agents, and their synergistic effects are true.
On the other hand, cytotoxic anticancer drugs will continue to be developed but their relative presence is expected to decline. I would like to offer a future cancer therapy scheme: The mainstay of anticancer therapy involves the use of targeted drugs, supplemented with cytotoxic anticancer drugs.
